Carasent ASA acquires Medrave Software AB

– We are very pleased to have completed this transaction with Medrave. Its complementary products will strengthen Carasent’s offering and provide cross-sale potential within primary and specialist care in Sweden. Medrave also aims to scale up its presence in the Norwegian market, which is well in line with our growth strategy in Norway, says Dennis Höjer, CEO of Carasent. 

Medrave was established in Sweden in 2007 by two doctors, Per Stenström and Svein Gjelstad. However, history dates back to 1997 when Per Stenström led an internal project in Region Stockholm to develop a reporting tool for quality improvement in primary care clinics. Medrave’s module-based software provides clinical reports to GPs, physiotherapists, child care, urgent care, youth care, mental health and habilitative care practices. The business intelligence solution automatically collects and sorts data, analyses and visualises, tracks and benchmarks KPIs, and provides automatic reporting. As such, healthcare professionals save time, get a better overview, reach goals more efficiently, and have consistent and improved reporting – ensuring safer patient care. 

– We are impressed by the module-based software solutions that the Medrave team has developed over many years and look forward to working with 16 new highly competent and motivated employees. The business intelligence solution developed by Medrave will expand our offering with a high-demand product among our customer base and enable us to service our clients in a new segment, the public healthcare sector. In summary, this transaction provides a strong rationale for adding a new product to our portfolio in line with communicated strategic priorities of expanding within the product, segment and geographical dimensions, Mr. Höjer adds.

 Medrave has an attractive customer base of more than 260 clients across Sweden and Norway, covering 1,646 practices and an estimated 8.8 million patients, with ~60% of revenue from the public sector in 2020. Medrave’s revenue and EBITDA were approximately SEK 23 million and SEK 6 million as per the last twelve months end of October 2021, with 99% recurring revenues and an annual recurring revenue (“ARR”) of approx. SEK 22 million. Medrave has delivered consistent historical organic growth of ~15% revenue compounded annual growth rate (“CAGR”) from 2017-2020. However, leveraging Carasent and Medrave’s combined scale and product offering in existing and new markets has great opportunities to accelerate the growth rate in the future. 

The purchase price will be SEK 134 million, corresponding to an enterprise value of SEK 125 million less Medrave’s consolidated net cash position of SEK 9 million (the (“Purchase Price”). 

The transaction purchase price will be settled as follows: 

– SEK 110 million of the Purchase Price in cash upon closing, 

– SEK 23.75 million will be reinvested by key employees in Carasent amounting to 627,391 consideration shares (corresponding to 18% of the Purchase Price), valued at a price of NOK 37.43 per share, corresponding to the 30-day volume weighted average price (“VWAP”) at 13 December 2021 (the “Reinvestment”). 

The completion of the acquisition is subject to customary closing conditions and is expected to close during January 2022. Carasent will host a webcast to present the acquisition on the 16th of December at 08:00 CET. The presentation will be given by Dennis Höjer, CEO and Svein Martin Bjørnstad, CFO. Please use the following link to access the presentation: https://channel.royalcast.com/landingpage/hegnarmedia/20211216_2/ The webcast will be held in English only and will include a live Q&A session. Carnegie acted as financial advisor to Carasent in connection with the transaction.